Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.
Atezolizumab, obinutuzumab, and venetoclax combination therapy is active in patients with untreated DLBCL-Richter’s Syndrome (RS).
This new research identifies some of the genetic changes that drive the evolution of CLL to Richter’s syndrome.
Early results from a phase 1b/2 trial show that epcoritamab has a manageable safety profile and an encouraging response rate in patients with Richter syndrome.
Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.
Our own Dr. Brian Koffman interviewed Dr. Nirav Shah, Associate Professor of Medicine at Medical College of Wisconsin, focusing on hematological malignancies. They discussed the latest results from a clinical trial of pirtobrutinib, a new reversible Bruton tyrosine kinase (BTK) inhibitor, for treating Richter transformation.
What follows is our patient-friendly summary of this research: Richter’s syndrome (RS), also known as Richter’s transformation, is a rare complication of chronic lymphocytic leukemia (CLL). It transforms into what is usually an aggressive lymphoma with a dismal prognosis.
In January 2022, CLL Society formally announced the launch of a new Research Program that is devoted to supporting underfunded areas of bench and translational science to make progress in the following four critical areas of unmet needs for those diagnosed with CLL / SLL:
We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.
One click to our most popular content.
